Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity - No Study Results Posted

Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP)

This study is currently recruiting participants.

Study NCT00622726 Information provided by The University of Texas Health Science Center, Houston

First Received: February 13, 2008 Last Updated: November 9, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	October 2010
Estimated Primary Completion Date:	October 2010 (Final data collection date for primary outcome measure)